
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lixivaptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycystic Kidney, Autosomal Dominant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 26, 2022
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Palladio Biosciences Doses First Patient With Lixivaptan in The ALERT Study
Details : The ALERT Study, designed to assess the safety of lixivaptan in autosomal dominant polycystic kidney disease (ADPKD) patients who previously discontinued therapy with tolvaptan due to liver toxicity, is currently recruiting patients in the United States.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2020
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation will include the results of more than 12 months of safe treatment with lixivaptan in this study, which was conducted as an expanded access clinical study under an IND.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2020
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lixivaptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycystic Kidney, Autosomal Dominant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 05, 2019
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Details : Lixivaptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycystic Kidney, Autosomal Dominant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2019
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lixivaptan
Therapeutic Area : Nephrology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
Details : Lixivaptan is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Polycystic Kidney Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 24, 2018
Lead Product(s) : Lixivaptan
Therapeutic Area : Nephrology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lixivaptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Polycystic Kidney, Autosomal Dominant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2018
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
